iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Share-Based Compensation (Tables)

Share-Based Compensation (Tables)

9 Months Ended

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):

	Three Months Ended
	March 31,
	2016		2015
Research and development	$	6	$	-
General and administrative		291		224
Totals	$	297	$	224

	Nine Months Ended
	March 31,
	2016		2015
Research and development	$	15	$	-
General and administrative		925		690
Totals	$	940	$	690

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes all stock option activity during the nine months ended March 31, 2016:

					Weighted-
			Weighted-		average
			average		Remaining		Aggregate
	Stock		Exercise		Contractual		Intrinsic Value
	Options		Price		Term (in years)		(in thousands)
Outstanding as of July 1, 2015		9,523,334	$	1.22		6.6	$	1,848
Granted		2,750,000		1.64
Outstanding as of March 31, 2016		12,273,334	$	1.31		6.6	$	479
Vested and, as of March 31, 2016, expected to vest		12,212,641	$	1.31		6.6	$	479

Exercisable as of March 31, 2016		7,455,024	$	1.31		5.3	$	417

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:

Risk-free interest rate	1.83% - 2.13	%
Dividend yield	0	%
Volatility	109.49% - 112.17	%
Expected term (in years)	9